美国食品和药物管理局向远程医疗公司发出30封警告信, FDA issues 30 warning letters to telehealth firms for falsely claiming compounded GLP-1 drugs are equivalent to approved versions.

林业发展局向远程保健公司发出30封警告信,因为错误地声称GLP-1复合药物相当于林业发展局核准的药物,强调这些未经批准的产品缺乏严格的安全和质量审查。 The FDA issued 30 warning letters to telehealth companies for falsely claiming compounded GLP-1 drugs are equivalent to FDA-approved versions, stressing these unapproved products lack rigorous safety and quality reviews. 该机构正在打击误导性直接对消费者的广告,将那些在不披露实际化合物的情况下以品牌名称推销复合药物的公司作为打击目标。 The agency is cracking down on misleading direct-to-consumer ads, targeting companies that promote compounded drugs under brand names without disclosing the actual compounder. 在此之前采取了更广泛的行动,包括40多封警告信和100份停止和销毁通知,加强对外国来源的活性成分和进口限制的监督。 This follows broader actions including over 40 warning letters and 100 cease-and-desist notices, with intensified scrutiny on foreign-sourced active ingredients and import restrictions. 这一行动的目的是在对不受管制的复合做法日益关切的情况下保护公共健康。 The move aims to protect public health amid rising concerns over unregulated compounding practices.